Extreme temperature deaths expected to surge in US by 2065 due to rising emissions

Severe temperature-related mortality in the US is projected to rise significantly by 2065, necessitating focused interventions for at-risk populations.

Gilead aims to cash in on liver disease wave with $4.6bn CymaBay deal – Pharmaceutical Technology

Share this article Gilead Sciences announced a $4.6bn acquisition of CymaBay Therapeutics, expanding its liver disease portfolio. Credit: SOPA Images via Getty Images. Gilead Sciences

February 13, 2024

Broncos scouting report: How Denver matches up with Steelers and predictions – The Cannabist

Justin Fields’ biggest critics will harp on his arm talent. Last season, the Broncos learned to avoid listening to the naysayers. The post Broncos scouting

September 13, 2024

ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease – Biotech Investments

EQS-News: ActiTrexx GmbH / Key word(s): Study ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease 19.03.2024 / 10:00 CET/CEST The

March 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.